Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

Allogeneic Hematopoietic Cell Transplantation Outcomes After Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (CA209-039 and CheckMate 205)

Carlo-Stella C. et al, (2017), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 17, S326 - S327

Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial

Jaeger U. et al, (2017), ONCOLOGY RESEARCH AND TREATMENT, 40, 13 - +

DEVELOPMENT OF A NEW HAEMATOLOGICAL MALIGNANT PATIENT-REPORTED OUTCOME MEASURE FOR USE IN CLINICAL PRACTICE: HM-PRO

Goswami P. et al, (2017), HAEMATOLOGICA, 102, 602 - 602

IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN

Hiddemann W. et al, (2017), HAEMATOLOGICA, 102, 314 - 314

Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Chen RW. et al, (2017), JOURNAL OF CLINICAL ONCOLOGY, 35

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

Noy A. et al, (2017), Blood, 129, 2224 - 2232

Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.

Eyre TA. et al, (2017), British journal of haematology

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.

Ait-Tahar K. et al, (2017), Adv Hematol, 2017

Toward a Biology-Driven Treatment Strategy for Peripheral T-cell Lymphoma.

Hildyard C. et al, (2017), Clin Med Insights Blood Disord, 10

Toward a biology-driven treatment strategy for peripheral T-cell lymphoma

Hildyard CAT. et al, (2017), Clinical Medicine Insights: Blood Disorders, 10

A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma

Collins GP. et al, (2016), BLOOD, 128

Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Timmerman JM. et al, (2016), BLOOD, 128

Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade)

Roemer MGM. et al, (2016), BLOOD, 128

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

Armand P. et al, (2016), BLOOD, 128

Results of a Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101: Preliminary Safety and Activity in Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma Patients

Eyre TA. et al, (2016), BLOOD, 128

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

Noy A. et al, (2016), BLOOD, 128

A phase I trial to assess the safety, PK and PD of CXD101 in advanced cancer expressing the biomarker HR23B

Eyre TA. et al, (2016), Annals of Oncology, 27

Cumulative burden of disease: a relevant measure of the late side-effects of cancer treatment.

Aznar MC. et al, (2016), The Lancet. Oncology, 17, 1189 - 1190

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Younes A. et al, (2016), Lancet Oncol, 17, 1283 - 1294

The Experiences of Young Adults With Hodgkin Lymphoma Transitioning to Survivorship: A Grounded Theory Study.

Matheson L. et al, (2016), Oncol Nurs Forum, 43, E195 - E2014